Jason R. Kelly - 20 Jan 2023 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role: CEO & Founder, Director
Signature: /s/ Karen Tepichin, Attorney-in-Fact
Issuer symbol: DNA
Transactions as of: 20 Jan 2023
Transactions value $: -$505,667
Form type: 4
Filing time: 24 Jan 2023, 16:30:26
Previous filing: 20 Jan 2023
Next filing: 26 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DNA	Class A Common Stock	Sale	-$254K	-152K	-0.97%	$1.67	15.5M	20 Jan 2023	Direct	F1
transaction	DNA	Class A Common Stock	Sale	-$252K	-144K	-0.93%	$1.75	15.4M	23 Jan 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.

Content

Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.

Remarks:

CEO & Founder